Online ISSN: 1945-4589
Learn about our FREE Post-Publication Promotion Services
Review Volume 6, Issue 11 pp 913—920

Questioning the preclinical paradigm: natural, extreme biology as an alternative discovery platform

Rochelle Buffenstein1, , O. Lynne Nelson2, , Kevin C. Corbit ,

  • 1 Barshop Institute for Aging and Longevity Studies, University of Texas Health Science Center at San Antonio, TX University of Texas Health Science Center at San Antonio, TX USA
  • 2 Department of Veterinary Clinical Sciences, Washington State University, Pullman, WA 9916, USA

Received: October 6, 2014       Accepted: November 30, 2014       Published: December 4, 2014      

https://doi.org/10.18632/aging.100704
How to Cite

Copyright: © 2014 Buffenstein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The pace at which science continues to advance is astonishing. From cosmology, microprocessors, structural engineering, and DNA sequencing our lives are continually affected by science-based technology. However, progress in treating human ailments, especially age-related conditions such as cancer and Alzheimer's disease, moves at a relative snail's pace. Given that the amount of investment is not disproportionately low, one has to question why our hopes for the development of efficacious drugs for such grievous illnesses have been frustratingly unrealized. Here we discuss one aspect of drug development –rodent models – and propose an alternative approach to discovery research rooted in evolutionary experimentation. Our goal is to accelerate the conversation around how we can move towards more translative preclinical work.

“My iPhone just told me I turn 86 today. Do you think you can hurry up with that cure?” – Jean Corbit, grandmother of the corresponding author

The Current Preclinical Paradigm

For more than a century, most biomedical research has relied primarily on mice and rats to study the basic biology, progression, and prevention of disease, with the overarching premise that “below the skin” all organisms are molecularly and biochemically alike. Indeed, several seminal discoveries and human therapies have been made using the premise of rodent models. However, advances in certain areas, especially age-related diseases, have been slow. In fact, one can argue that the numerous reported ‘cures’ for rodent obesity, cancer, and Alzheimer's disease have ultimately burdened the collective resources of the community to the point that a re-evaluation of the preclinical paradigm must be undertaken.

With the advent of transgenic rodent technologies, a revolution of new discoveries and ideas was ushered in. Particularly in the field of Developmental Biology, both loss- and gain-of-function genetic experiments elucidated many of the major pathways governing gastrulation, patterning, and embryonic development in general. Indeed, so stereotypical is vertebrate development that to the untrained eye it can be difficult to discern early mouse and human embryos.

However, animals diverge developmentally, behaviorally, and metabolically postpartum, most notably in adulthood. Because of this the applicability of rodent disease models has been called into question (e.g. see the European Commission workshop report at http://ec.europa.eu/research/health/pdf/summary-report-25082010_en.pdf and [1]). This is particularly evident in diseases such as obesity, where aberrations in body weight are appreciated in ~1/3 of mouse knockouts [2]. Indeed, almost every developmental pathway – BMP [3], TGFβ[4] FGF [5], VEGF [6], Hedgehog [7], Wnt [8], and Notch [9] – have been reported to be anti- or pro-obesogenic. It is difficult to rationalize why mammals would evolve such that perturbation of any signaling pathway would affect body mass, especially weight loss.

Specifically, the issue is not ‘reverse translation’ – drugs that are clinically successful in humans having effects in rodents -in fact many do [1], but instead the many ‘cures’ reported in mice fail once reaching human clinical trials. It is difficult to fully appreciate the magnitude of the problem until being immersed in the world of drug development, possibly due to a lack of appropriate publication outlets for such ‘negative data’. With such disparity between mouse and human efficacy, major biotechnology and pharmaceutical companies have invested heavily in human genetics (e.g. see http://wwwext.amgen.com/media/media_pr_detail.jsp?releaseID=1765710 and http://www.nytimes.com/2014/01/13/business/aiming-to-push-genomics-forward-in-new-study.html?_r=0). With success stories such as PCSK9 [10, 11] the hope is to shine a spotlight on high-value targets in a sea of positive data derived from rodents.

The Workhorse of Discovery Biology

One mouse strain in particular, C57Bl/6, predominates studies to investigate molecular mechanisms of disease and evaluate putative therapies (for a robust commentary read Daniel Engber's piece in Slate: http://www.slate.com/articles/health_and_science/the_mouse_trap/2011/11/black_6_lab_mice_and_the_history_of_biomedical_research.html). There are many advantages to using this well characterized and highly inbred mouse strain, most notably these rodents are amenable to genetic manipulation and acquired data using this reductionist approach are highly reproducible. Moreover mice rapidly attain sexual maturity, have good breeding success in captivity and develop many of the diseases that commonly afflict humans. As such, it is inferred that experimental findings in C57Bl/6 mice apply to all mammals including humans. Disappointingly, many of the promising preclinical findings based upon lab rodents have not translated into effective and safe biomedical discoveries for human therapies [12]. This may reflect, in part, that these genetically engineered mice have been selected for rapid growth, cancer susceptibility and short-lives and naturally have poor defenses against environmental toxins and disease. Supporting this premise are findings that C57Bl/6 mice live only half as long as predicted on the basis of body size [13] and have shorter lifespans than their more genetically diverse wild-caught counterparts [14].

Another possible explanation for their short-lifespans and early onset of age-associated diseases may be linked to the animal husbandry conditions. In most research facilities mice are maintained in a manner geared towards the comfort and convenience of the human animal-attendants such that rodents are housed in temperature- and light-controlled, specific pathogen free facilities. Furthermore, they are kept in small cages, which restrict exercise and access to copious enrichment. These germ-free animals exhibit artificial neuroendocrine rhythms, do not have an inbuilt library of antibodies to deal with pathogens, and are very vulnerable to environmental stressors. Also, animals with little mental or physical stimulation often become obese, express different proteome profiles from exercised animals, and may develop a suite of pathological conditions that may constrain or confound the pertinence of research based findings [15]. Finally, mice living below thermoneutrality (21-24°C) expend half of their daily energy expenditure on facultative thermogenesis alone and, as a result, chronically cold-stressed mice eat twice as much as mice housed at 28-30°C [16]. Normalizing metabolic homeostasis in various models using such hypermetabolic animals may be setting the bar a bit low.

Data obtained from animals housed individually or in groups in which they can huddle together and behaviorally thermoregulate, especially with regard to drug treatments, markedly differ. For example, we have found, upon examining cardiac responses to doxorubicin, a widely used chemotherapy with concomitant cardiac toxicity, animals housed on their own fare considerably worse than those housed in groups (Grimes and Buffenstein, unpublished data). Moreover, mice housed under standard sub-thermoneutral temperatures are more susceptible to tumor growth [17].

It has been reported that ad libitum fed, sedentary mice exhibit reduced cognitive function and commonly present with similar pathophysiology to those of morbidly obese humans [18, 19]. Astonishingly, these individuals would be commonly considered “unhealthy” by human criteria yet are routinely used as experimental “controls” with which to evaluate the efficacy of a treatment or experimental intervention. Not surprisingly, interventions that reduce food intake (i.e. dietary restriction) or enable the animals to increase energy expenditure through exercise or participate in mentally challenging activities commonly show beneficial and life-extending effects [20-23]. Conversely, if these sedentary rodents are subjected to high fat diets or other sub-optimal husbandry conditions they commonly become even more susceptible to oxidative stress and glucose dysregulation, and as such may be more responsive to experimental manipulations to reduce oxidative stress, or drugs that treat metabolic syndrome [24, 25].

Evolutionary Experimentation as a New Paradigm

There is a growing call for additional discovery tools in biomedical research that provide more translative predictability for diseases that generally afflict humans in later life. Animal models that are considered long-lived on the basis of their body size are essential to fill the gap assessing the immutable role of time in aging and the manifestation of age-related diseases. Use of extremely long-lived models such as the naked mole-rat, [26] or species that have adapted to extreme environments [27-29] also enables one to evaluate whether nature has already evolved the appropriate mechanisms to overcome the environmental threats that contribute to sporadic and late onset diseases.

An alternative approach towards target discovery employs natural, extreme biology where evolutionary experimentation has overcome many biological challenges [30-33]. For instance, obesity is a natural and necessary state to survive months of fasting in hibernating animals. To this end we studied grizzly bears (Ursus arctos horribilis) before, during, and after hibernation to determine the effects of natural obesity on insulin sensitivity and cardiac function.

The Metabolic Adaptations Governing Hibernation

Mammalian hibernation is a distinct adaptive strategy that intrigues scientists due to an impressive display of extreme and flexible metabolism. Hibernation is most commonly defined as a series of physiological alterations in various tissues that give an animal the ability to survive long periods of nutritional deprivation by dramatically reducing energy metabolism [34]. The sum of these adaptations results in a radical departure from the normal physiological homeostasis that is seen in most mammals. Numerous species, including primates, manifest a torpid phenotype linked to nutrient availability or thermal challenges, although the characteristics of the hypometabolic state can be quite different among estivators and hibernators, and even within both small- and large-sized hibernators marked interspecific differences are evident.

Ground squirrels (Spermophilus spp.) are often considered the prototypical hibernator as individuals in this genus transition from an active, euthermic state (37oC) to a hibernating state where torpid body temperature commonly falls to 3-5oC. During the hibernation cycle, these animals may be completely inactive for weeks at a time at near freezing body temperatures, but exhibit repeated arousal bouts to euthermy lasting approximately 24 hours [35-38]. Ground squirrels are nonresponsive during bouts of torpor, but awaken during periodic interbout arousals. In contrast, the larger species of the genus Ursus maintain a considerably more homogenous hibernation state than ground squirrels, as bears maintain near normal body temperatures and cyclic interbout arousal periods are absent [39, 40]. In general, bears are not unconscious and may be easily disturbed during hibernation, often appearing quite alert [41-43]. Bears hibernate for 4-6 months without nutritional intake, whereas many small hibernators arouse every 4-10 days to feed [44, 45]. As such, bear hibernation may represent the most refined response to dormancy of any mammal.

Three states of insulin sensitivity in bears

To cope with the food scarcity of winter many mammals enter a hyperphagic period in late summer and early autumn to store sufficient fat necessary to fuel months of fasting. During this preparatory phase bears double total body fat and increase body weight by 30-50%. To understand the metabolic consequences of such acute fat and weight accumulation, we assayed insulin responsiveness in bears during three seasons: autumn (pre-hibernation in October when the bears are most obese), winter (hibernation in January), and spring (April/May following arousal from hibernation but before mating or hyperphagia). We uncovered three distinct states of insulin sensitivity – a typical response in spring, augmented sensitivity in autumn, and resistance during hibernation [46].

Interestingly, the increased insulin sensitivity observed in obese bears preparing for hibernation occurs selectively in adipose tissue. Specifically, bears shut down the lipid phosphatase PTEN to promote AKT activity and heighten insulin responsiveness. This is at least partially governed by a phosphorylation event on serine 380 (S380) of PTEN that is not observed in other tissues such as liver and skeletal muscle, suggesting the intriguing possibility of an adipose tissue-specific PTEN S380 kinase that could be a target to develop insulin-sensitizing drugs. Work demonstrating that PTEN haploinsufficient humans are exquisitely insulin responsive and simultaneously obese makes them not only similar to autumn bears, but also supports the existence of an evolutionarily conserved mechanism of adipose tissue-specific insulin sensitization [47]. We propose that bears developed reversible insulin resistance to govern fat metabolism; augmented adipose tissue insulin sensitivity in autumn to promote fat storage and hibernation-specific insulin resistance to mediate lipolysis and obligate use of fat as the predominant fuel source to survive prolonged fasting. Our results using natural, extreme biology add to an emerging paradigm where diabetes and obesity - in contrast to the prevailing notion that the two always go hand-in-hand - may exist naturally on opposite ends of the metabolic spectrum. Finally, given that the amount of circulating insulin does not change during the sensitive-resistant cycle and bears exist with relatively low levels of insulin, rigorously testing the idea of lowering insulin levels to treat diabetes and obesity may have evolutionary rationale [48-51].

Cardiac adaptions during hibernation

Both ground squirrels and bears dramatically reduce heart rate and cardiac output during hibernation relative to the active state. However, divergent cardiac phenotypes and adaptive strategies are manifest by the two species. For example, grizzly bears maintain a normal stroke volume while reducing cardiac muscle mass and muscle compliance during hibernation, opposite to what is observed in ground squirrels [52-54]. The maintenance of stroke work with smaller cardiac muscle mass by the bear is unique in that chronic, prolonged diastolic filling is typically associated with eccentric remodeling (dilation) resulting in larger muscle mass. However, a chamber that increases in stiffness is less likely to distend or dilate. Indeed, a part of the bears' adaptation to hibernating at very low heart rates is to alter the characteristics of the cardiac muscle. Upregulation of the stiff sarcomeric protein, titin (N2B isoform), compensates for the reduced cardiac muscle mass by increasing muscle stiffness and normalizing ventricular wall stress with associated with prolonged diastolic filling at low heart rates. [55] Correlations between titin expression and ventricular diastolic function have been observed in humans [56, 57]. In dilated cardiomyopathy, increased titin N2BA isoform expression results in a decrease in ventricular stiffness, which may be important in reducing ventricular filling pressures for a given volume (reducing symptoms of congestion) [58]. However, increased N2BA expression has been correlated with a negative effect on systolic function and worsening heart failure [56, 59]. Understanding the mechanisms that allow for preserved function yet maintenance of a lower muscle mass in an energetically costly organ such as heart may constitute important treatment strategies to reduce overall cardiac workload in disease.

Throughout their evolutionary history, bears have naturally solved ways to avoid the negative consequences of low cardiac output and heart rate, and yet remain homeothermic and responsive. Given that the protein and gene regulations presently identified in hibernation are not novel and are shared by all other mammals, what are the potential applications of this physiology to non-hibernating mammals? Comparative physiologic studies involving some form of biomimcry could result in improved treatment strategies for cardiac disease in humans.

Extremophiles, Aging, and Peto's Paradox

The fascinating biology of the grizzly bear's evolved armory against the vagaries of hibernation serves to remind us that many seminal discoveries in biomedical sciences have been serendipitously found employing unusual animal models. Comparative physiological and evolutionary studies involving animals inhabiting extreme habitats has repeatedly shed light on elusive biomedical questions and basic biology. Not surprisingly, some of these “extremophiles” (a term used more loosely here than to simply refer to members of the domains Archea and Bacteria, microbes known to live in particularly inhospitable habitats) have been co-opted into the “traditional” biomedical animal model bestiary.

C. elegans as an idiosyncratic model organism for biomedical research

One such species is Caenorhabditis elegans, a soil-dwelling microscopic, hermaphroditic roundworm. C.elegans shares multicellular complexity and signaling pathways with higher organisms. This together with its short-lifespan, ease of standardized husbandry and genetic manipulation have rendered it a particularly useful model for high throughput functional genomic screens of novel drug targets [60]. C.elegans has led to significant findings regarding the highly conserved insulin signaling pathway among metazoans [61] and in particular the role thereof in longevity [62, 63]. Over the last fifty years, every biological aspect of this unsegmented pseudocoelomate has been extensively studied, providing fundamental insights into developmental biology, genomics, neurobiology, and aging (see http://www.wormbook.org/NCBI). Indeed, research based upon this unusual worm has resulted in three Nobel prizes for Medicine.

Methuselah models for aging research

In aging studies among mammals two species stand out as being exceptionally long-lived, namely, naked mole-rats and humans, both living ~5 times longer than predicted allometrically. This mouse-sized, 30 year-living rodent exhibits very few age-associated declines, maintaining body composition, heart health, bone quality, and reproductive capacity for at least 24 years [26, 64-66]. Strikingly, the naked mole-rat, although it does not employ torpor, shares many similar physiological features with those of hibernating mammals; both basal heart rate and metabolic rate are lower than predicted on the basis of body size [65]. Echocardiography revealed that all left ventricular functional parameters were substantially lower than those of mice indicating that their hearts are “idling on low” and border on levels considered to represent pathological left venticular systolic dysfunction in humans [67]. Moreover, naked mole-rats show extreme tolerance to pronounced thermolability as well as oxygen and nutrient availability [68-71], features considered highly adaptive to life under the extreme conditions encountered in xeric subterranean habits. Another adaptive feature to life in arid habitats are low fasting blood glucose levels and a reliance on volatile fatty acids, derived from the fermentation of cell walls by gut microbiota, as a predominant fuel source [72]. Finally, following both grizzly bears and the aging paradigm in general, naked mole-rats are exquisitely sensitively to and have very low circulating levels of insulin [73, 74].

Cancer resistant animal models

Another unusual characteristic of naked mole-rats, shared with much larger bears and blue whales [75], is that, unlike most mammals, cancer is extremely rare. Naked mole-rat differences in cancer susceptibility are attributed to greatly enhanced stringency for proliferative control (e.g., p53, pRb, and the Ras/MAPK pathway) and over-expression of genes both encoding products that protect DNA during transcription and promote xenobiotic detoxification [76-79].

Indeed, in most multicellular animals, incidence of cancer ranges between 20-50% [80, 81], regardless of phylogeny, body size and the evolution of multiple defense mechanisms to protect genomic stability. Mutational frequency is known to be similar in cells of all species and, as such, the accrual of mutations ought to depend upon the number of cell divisions, rendering larger species (e.g. blue whales) with a greater number of cells more prone to malignancy the smaller animals (e.g. mice). Moreover, although long-lived species intuitively should exhibit more DNA mutations by the end of life than observed in short-lived species, cancer incidence generally is the same or greater in short-lived species [82, 83], a phenomenon commonly referred to as Peto's paradox [84]. As such, although most elderly individuals have numerous cells with the requisite mutations necessary for cancer initiation, the progression into invasive cancer is relatively rare. This is not attributable to efficient DNA repair pathways; rather it has been proposed that extraneous factors within the cellular milieu disturb normal cell signalling pathways, promoting cancer progression and metastasis and may be directly linked to metabolic profiles [81]. Given the critical role of the metabolic milieu in cancer progression, data acquired from cancer cells maintained under optimal culture conditions may have limited translational potential, findings that have been confirmed in assessments of effective drug treatments [85]. Similarly, experimentally induced cancer initiation in highly inbred mouse models may not be ideal models for the complexity of human cancer progression and metastasis [86].

A common feature shared by species that exhibit a relatively low rate of cancer incidence is comparatively low mass-specific metabolic rates. Altered cellular metabolism, particularly in response to glucose dysregulation and obesity, has been strongly implicated in multiple human cancers [87]. Indeed, an altered cancer risk in immigrants taking on a Westernized lifestyle has been appreciated [88]. Lack of physical activity coupled with obesity and associated changes in circulating levels of insulin, IGF, mTOR and associated kinases have been strongly implicated in this regard. Indeed it appears that a positive energy balance and the anabolic metabolic pathways involved in this regard play a dominant role in the severity of cancer progression. While this evolutionarily conserved pathway is essential for synchronizing growth and repair to match energy availability and thereby ensure survival of the organism, many of the intermediates in this nutrient sensing pathway are tumor suppressor proteins (e.g., PTEN and LKB1). Chronic activation of PI3 kinase signaling, by elevated blood glucose in diabetes or metabolic syndrome, may thus increase the risk of the development of cancer, leading to a metabolic switch favoring aerobic glycolysis and cell proliferation [89, 90]. Preternaturally cancer-resistant naked mole-rats have naturally have low insulin and mTOR signaling [91] that may protect them against tumorigenesis. Similarly, very few incidences of cancer have been reported in grizzly bears, or even bears in general [92-94], that, like the naked mole-rat, may downregulate mTOR signaling, albeit seasonally [46]. Understanding how environmentally induced changes in neuroendocrine signaling influence proliferative phenoplasticity and prevent age-associated diseases commonly linked to metabolic dysfunctions may lead to paradigm shifts in our approaches to targeted drug discovery. The paramount question is, however, if what is ultimately discovered from evolved natural cancer resistance can be applied to the reversal of established cancers in humans.

Closing remarks

In 1950, C. Ladd Prosser wrote “Comparative Physiology is not so much a defined discipline as a viewpoint, a philosophy”. We believe it is worth examining if this philosophy extends to the discovery of more predictive targets for drug development. When biological findings are rooted in the natural adaptations of evolutionary pressures the governing mechanisms are likely to be conserved, as opposed to when artificial genes, diets, and environments are imposed upon rodents. For instance, when mice lacking an immune system are injected with human tumor cells, or when inbred mice have their left coronary arteries tied off, or obesity-prone mice are fed a human ‘cafeteria’ diet, the reaction from animals never exposed to such insults can be anything but natural. Decades of brilliant science, exciting findings, and substantial investment have far too often not translated when put to the challenge of human clinical trials. An alternative approach utilizes carefully chosen extremophiles that have evolved genes, proteins, and mechanisms to naturally counter disease-inducing insults and ultimately follows Orgel's second rule: “Evolution is cleverer than you are”. As a community we need to reconsider the future of preclinical research if we are to obtain broader measures of success in treating the grievous illnesses that face us today.

Acknowledgments

We are deeply indebted to Dr. Charlie Robbins and the entire Washington State University Bear Center team.

Conflicts of Interest

The authors of this manuscript declare no conflict of interest.

References

  • 1. Vickers SP, Jackson HC, Cheetham SC. The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. 2011; 164:1248-1262. [PubMed]
  • 2. Smemo S, et al. Obesity-associated variants within FTO form long-range functional connections with IRX3. Nature. 2014; 507:371-375. [PubMed]
  • 3. Townsend KL, et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J. 2012; 26:2187-2196. [PubMed]
  • 4. Yadav H, et al. Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab. 2011; 14:67-79. [PubMed]
  • 5. Kharitonenkov A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005; 115:1627-1635. [PubMed]
  • 6. Lu X, et al. Resistance to obesity by repression of VEGF gene expression through induction of brown-like adipocyte differentiation. Endocrinology. 2012; 153:3123-3132. [PubMed]
  • 7. Pospisilik JA, et al. Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell. 2010; 140:148-160. [PubMed]
  • 8. Wright WS, et al. Wnt10b inhibits obesity in ob/ob and agouti mice. Diabetes. 2007; 56:295-303. [PubMed]
  • 9. Bi P, et al. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nat Med. 2014; 20:911-918. [PubMed]
  • 10. Cohen J, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37:161-165. [PubMed]
  • 11. Robinson JG, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014; 311:1870-1882. [PubMed]
  • 12. Woodcock J and Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008; 59:1-12. [PubMed]
  • 13. de Magalhaes JP, Costa J, Church GM. An analysis of the relationship between metabolism, developmental schedules, and longevity using phylogenetic independent contrasts. J Gerontol A Biol Sci Med Sci. 2007; 62:149-160. [PubMed]
  • 14. Miller RA, et al. Longer life spans and delayed maturation in wild-derived mice. Exp Biol Med (Maywood). 2002; 227:500-508. [PubMed]
  • 15. Martin B, et al. "Control" laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A. 2010; 107:6127-6133. [PubMed]
  • 16. Golozoubova V, et al. Depressed thermogenesis but competent brown adipose tissue recruitment in mice devoid of all hormone-binding thyroid hormone receptors. Mol Endocrinol. 2004; 18:384-401. [PubMed]
  • 17. Kokolus KM, et al. Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature. Proc Natl Acad Sci U S A. 2013; 110:20176-20181. [PubMed]
  • 18. Aguiar AS Jr., et al. Physical exercise improves motor and short-term social memory deficits in reserpinized rats. Brain Res Bull. 2009; 79:452-457. [PubMed]
  • 19. Martin B, et al. Sex-dependent metabolic, neuroendocrine, and cognitive responses to dietary energy restriction and excess. Endocrinology. 2007; 148:4318-4333. [PubMed]
  • 20. Garcia-Valles R, et al. Life-long spontaneous exercise does not prolong lifespan but improves health span in mice. Longev Healthspan. 2013; 2:14 [PubMed]
  • 21. Mercken EM, et al. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012; 11:390-398. [PubMed]
  • 22. Bravo-San Pedro JM and Senovilla L. Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY). 2013; 5:793-801. [PubMed]
  • 23. Si H, et al. High corn oil dietary intake improves health and longevity of aging mice. Exp Gerontol. 58C:2014; 244-249. [PubMed]
  • 24. Ristow M and Zarse K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp Gerontol. 2010; 45:410-418. [PubMed]
  • 25. Salmon AB, Richardson A, Pérez VI. Update on the oxidative stress theory of aging: Does oxidative stress play a role in aging or healthy aging? Free Radical Biology and Medicine. 2010; 48:642-655. [PubMed]
  • 26. Buffenstein R. Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. J Comp Physiol B. 2008; 178:439-445. [PubMed]
  • 27. Hochachka PW and Somero GN. Biochemical Adaptation, Mechanism and Process in Physiological Evolution. 2002; Oxford Oxford University Press.
  • 28. Ruf T and Geiser F. Daily torpor and hibernation in birds and mammals. Biol Rev Camb Philos Soc. 2014;.
  • 29. Abboud J and Storey KB. Novel control of lactate dehydrogenase from the freeze tolerant wood frog: role of posttranslational modifications. PeerJ. 2013; 1:e12 [PubMed]
  • 30. Rowe AH, et al. Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin. Science. 2013; 342:441-446. [PubMed]
  • 31. Seifert AW, et al. Skin shedding and tissue regeneration in African spiny mice (Acomys). Nature. 2012; 489:561-565. [PubMed]
  • 32. Smith ES, et al. The molecular basis of acid insensitivity in the African naked mole-rat. Science. 2011; 334:1557-1560. [PubMed]
  • 33. Tian X, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013; 499:346-349. [PubMed]
  • 34. Watts PD, et al. Mammalian Hibernation and the Oxygen-Consumption of a Denning Black Bear (Ursus, Americanas). Comparative Biochemistry and Physiology a-Physiology. 1981; 69:121-123..
  • 35. Caprette DR and Senturia JB. Isovolumetric performance of isolated ground squirrel and rat hearts at low temperature. Am J Physiol. 1984; 247:R722-727. [PubMed]
  • 36. Milsom WK, Burlington RF, Burleson ML. Vagal influence of heart rate in hibernating ground squirrels. J Exp Biol. 1993; 185:25-32..
  • 37. Hampton M, Nelson BT, Andrews MT. Circulation and metabolic rates in a natural hibernator: an integrative physiological model. Am J Physiol Regul Integr Comp Physiol. 2010; 299:R1478-1488. [PubMed]
  • 38. Barnes BM. Freeze avoidance in a mammal: body temperatures below 0 degree C in an Arctic hibernator. Science. 1989; 244:1593-1595. [PubMed]
  • 39. Hissa R, et al. Seasonal patterns in the physiology of the European brown bear (Ursus arctos arctos) in Finland. Comp Biochem Physiol A Physiol. 1994; 109:781-791. [PubMed]
  • 40. Toien O, et al. Hibernation in black bears: independence of metabolic suppression from body temperature. Science. 2011; 331:906-909. [PubMed]
  • 41. Evans AL, et al. Capture, anesthesia, and disturbance of free-ranging brown bears (Ursus arctos) during hibernation. PLoS One. 2012; 7:e40520 [PubMed]
  • 42. Folk GE Jr. and Nelson RA. The hibernation of polar bears: a model for the study of human starvation. Proc Intl Symp Cir Health. 1981; 5:617-619..
  • 43. Nelson RA, et al. Behavior, biochemistry and hibernation in black, grizzly and polar bears. Int Conf Bear Res and Manage. 1983; 5:284-290..
  • 44. Carey HV, Andrews MT, Martin SL. Mammalian hiberna-ion: cellular and molecular responses to depressed metabolism and low temperature. Physiol Rev. 2003; 83:1153-1181. [PubMed]
  • 45. Humphries MM, Thomas DW, Kramer DL. Torpor and digestion in food-storing hibernators. Physiol Biochem Zool. 2001; 74:283-292. [PubMed]
  • 46. Nelson OL, et al. Grizzly bears exhibit augmented insulin sensitivity while obese prior to a reversible insulin resistance during hibernation. Cell Metab. 2014; 20:376-382. [PubMed]
  • 47. Pal A, et al. PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med. 2012; 367:1002-1011. [PubMed]
  • 48. Alemzadeh R, et al. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J Clin Endocrinol Metab. 1998; 83:1911-1915. [PubMed]
  • 49. Lustig RH, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006; 30:331-341. [PubMed]
  • 50. Mehran AE, et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 2012; 16:723-737. [PubMed]
  • 51. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes. 2012; 61:4-13. [PubMed]
  • 52. Nelson OL and Rourke BC. Increase in cardiac myosin heavy-chain (MyHC) alpha protein isoform in hibernating ground squirrels, with echocardiographic visualization of ventricular wall hypertrophy and prolonged contraction. J Exp Biol. 2013; 216:4678-4690. [PubMed]
  • 53. Nelson OL and Robbins CT. Cardiac function adaptations in hibernating grizzly bears (Ursus arctos horribilis). J Comp Physiol B. 2010; 180:465-473. [PubMed]
  • 54. Brauch KM, et al. Digital transcriptome analysis indicates adaptive mechanisms in the heart of a hibernating mammal. Physiol Genomics. 2005; 23:227-234. [PubMed]
  • 55. Nelson OL, et al. Titin isoform switching is a major cardiac adaptive response in hibernating grizzly bears. Am J Physiol Heart Circ Physiol. 2008; 295:H366-371. [PubMed]
  • 56. Fukuda N, et al. Titin isoform variance and length dependence of activation in skinned bovine cardiac muscle. J Physiol. 2003; 553:147-154. [PubMed]
  • 57. Nagueh SF, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation. 2004; 110:155-162. [PubMed]
  • 58. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol. 1988; 12:426-440. [PubMed]
  • 59. Granzier H and Labeit S. Cardiac titin: an adjustable multi-functional spring. J Physiol. 2002; 541:335-342. [PubMed]
  • 60. Kaletta T and Hengartner MO. Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov. 2006; 5:387-398. [PubMed]
  • 61. Pinero Gonzalez J, et al. Conservation of key members in the course of the evolution of the insulin signaling pathway. Biosystems. 2009; 95:7-16. [PubMed]
  • 62. Kenyon C, et al. A C. elegans mutant that lives twice as long as wild type. Nature. 1993; 366:461-464. [PubMed]
  • 63. Larsen PL, Albert PS, Riddle DL. Genes that regulate both development and longevity in Caenorhabditis elegans. Genetics. 1995; 139:1567-1583. [PubMed]
  • 64. Edrey YH, et al. Successful aging and sustained good health in the naked mole rat: a long-lived mammalian model for biogerontology and biomedical research. ILAR J. 2011; 52:41-53. [PubMed]
  • 65. Grimes KM, et al. Getting to the heart of the matter: age-related changes in diastolic heart function in the longest-lived rodent, the naked mole rat. J Gerontol A Biol Sci Med Sci. 2012; 67:384-394. [PubMed]
  • 66. Pinto M, et al. Lack of sexual dimorphism in femora of the eusocial and hypogonadic naked mole-rat: a novel animal model for the study of delayed puberty on the skeletal system. Bone. 2010; 46:112-120. [PubMed]
  • 67. Grimes KM, et al. Cardiac function of the naked mole-rat: ecophysiological responses to working underground. Am J Physiol Heart Circ Physiol. 2014; 306:H730-737. [PubMed]
  • 68. Larson J and Park TJ. Extreme hypoxia tolerance of naked mole-rat brain. Neuroreport. 2009; 20:1634-1637. [PubMed]
  • 69. LaVinka PC and Park TJ. Blunted behavioral and c Fos responses to acidic fumes in the African naked mole-rat. PLoS One. 2012; 7:e45060 [PubMed]
  • 70. Hislop MS and Buffenstein R. Noradrenaline induces nonshivering thermogenesis in both the naked mole-rat (Heterocephalus glaber) and the Damara mole-rat (Cryptomys damarensis) despite very different modes of thermoregulation. Journal of Thermal Biology. 1994; 19:25-32..
  • 71. Buffenstein R and Yahav S. Is the naked mole-rat Heterocephalus glaber a poikilothermic or poorly thermoregulating endothermic mammal? Journal of Thermal Biology. 1991; 16:227-232..
  • 72. Buffenstein R and Yahav S. The effect of diet on microfaunal population and function in the caecum of a subterranean naked mole-rat, Heterocephalus glaber. Br J Nutr. 1991; 65:249-58. [PubMed]
  • 73. Kramer B and Buffenstein R. The pancreas of the naked mole-rat (Heterocephalus glaber): an ultrastructural and immunocytochemical study of the endocrine component of thermoneutral and cold acclimated animals. Gen Comp Endocrinol. 2004; 139:206-214. [PubMed]
  • 74. Edrey YH, et al. Endocrine function and neurobiology of the longest-living rodent, the naked mole-rat. Exp Gerontol. 2011; 46:116-123. [PubMed]
  • 75. Newman SJ and Smith SA. Marine mammal neoplasia: a review. Vet Pathol. 2006; 43:865-80. [PubMed]
  • 76. Kim EB, et al. Genome sequencing reveals insights into physiology and longevity of the naked mole rat. Nature. 2011; 479:223-227. [PubMed]
  • 77. Yu C, et al. RNA sequencing reveals differential gene expression of mitochondria and oxidation reduction genes in the long-lived naked mole-rat when compared to mice. PlosOne. 2011; 6:e26729.
  • 78. Azpurua J, et al. Naked mole-rat has increased translational fidelity compared with the mouse, as well as a unique 28S ribosomal RNA cleavage. Proc Natl Acad Sci U S A. 2013; 110:17350-17355. [PubMed]
  • 79. Keane M, et al. The Naked Mole Rat Genome Resource: facilitating analyses of cancer and longevity-related adaptations. Bioinformatics. 2014;.
  • 80. Leroi AM, Koufopanou V, Burt A. Cancer selection. Nat Rev Cancer. 2003; 3:226-231. [PubMed]
  • 81. Caulin AF and Maley CC. Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol. 2011; 26:175-182. [PubMed]
  • 82. Harper JM, Leathers CW, Austad SN. Does caloric restriction extend life in wild mice? Aging Cell. 2006; 5:441-449. [PubMed]
  • 83. Ikeno Y, et al. Reduced Incidence and Delayed Occurrence of Fatal Neoplastic Diseases in Growth Hormone Receptor/Binding Protein Knockout Mice. Journals of Gerontology Series a-Biological Sciences and Medical Sciences. 2009; 64:522-529..
  • 84. Peto R, et al. Cancer and ageing in mice and men. Br J Cancer. 1975; 32:411-426. [PubMed]
  • 85. Zeng L, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer. 2010; 17:539-551. [PubMed]
  • 86. Begley CG and Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483:531-533. [PubMed]
  • 87. Wicki A and Hagmann J. Diet and cancer. Swiss Med Wkly. 2011; 141:w13250 [PubMed]
  • 88. Holly JM, Zeng L, Perks CM. Epithelial cancers in the post-genomic era: should we reconsider our lifestyle? Cancer Metastasis Rev. 2013; 32:673-705. [PubMed]
  • 89. Chalhoub N and Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009; 4:127-150. [PubMed]
  • 90. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res. 2010; 70:859-862. [PubMed]
  • 91. Fang X, et al. Adaptations to a Subterranean Environment and Longevity Revealed by the Analysis of Mole Rat Genomes. Cell Rep. 2014; 8:1354-1364. [PubMed]
  • 92. Goodwin WE, Deklerk JN, McGoon DC. A malignant testis tumor with hepatic metastasis in a grizzly bear. J Urol. 1953; 69:845-848. [PubMed]
  • 93. Blancquaert AM, et al. Lymphosarcoma with perforation of the ileum in a grizzly bear. Journal of the American Veterinary Medical Association. 1984; 185:1433-1435. [PubMed]
  • 94. Mete A, et al. Disseminated Pleomorphic Myofibrosarcoma in a Grizzly Bear (Ursus arctos horribilis). Journal of Comparative Pathology. 2012; 147:376-380. [PubMed]
Download PDF
Corresponding Author

Kevin C. Corbit, PhD
kevinccorbit@gmail.com

Keywords
preclinical models extremophiles grizzly bear insulin sensitivity obesity cardiac function naked mole-rat aging cancer resistance
Paper Sections